Regencell Bioscience Balance Sheet
NASDAQ: RGCHealth Care Medicinal Chemicals and Botanical Products USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regencell Bioscience financial position
At the end of fiscal 2026, Regencell Bioscience reported total assets of $14.7 million, up 155.9% from a year earlier against total liabilities of $1.4 million. Shareholders' equity stood at $13.3 million, or 90.6% of assets. The company held $14.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.77, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Regencell Bioscience balance sheet (annual)
| Fiscal year (USD) | FY 20262026-06-30 | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 14.19M | 2.42M | 2.96M | 1.56M | 6.42M | 59.41K | 386.98K | 243.31K |
| Short-Term Investments | — | 2.48M | 5.00M | 10.00M | 10.00M | — | — | — |
| Total Current Assets | 14.22M | 4.90M | 8.11M | 11.62M | 16.44M | 66.85K | 386.98K | — |
| Property, Plant & Equipment | 135.11K | 215.43K | 141.73K | 440.83K | 712.59K | 81.86K | 108.32K | — |
| Total Assets | 14.73M | 5.76M | 8.44M | 12.62M | 18.02M | 340.13K | 514.02K | — |
| Total Current Liabilities | 1.32M | 663.67K | 193.58K | 606.91K | 577.76K | 4.34M | 3.16M | — |
| Total Liabilities | 1.38M | 895.31K | 219.51K | 632.32K | 938.03K | 4.34M | 3.16M | — |
| Shareholders' Equity | 13.35M | 4.86M | 8.22M | 12.03M | 17.07M | -4.00M | -2.65M | -1.84M |
| Retained Earnings | -36.90M | -25.20M | -21.62M | -17.32M | -11.44M | -4.00M | -2.65M | — |
| Net Cash (Debt) | 14.19M | 4.90M | 7.96M | 11.56M | 16.42M | 59.41K | 386.98K | 243.31K |
| Shares Outstanding | 495.88M | 494.49M | 494.49M | 13.01M | 13.01M | 10.00M | 10.00M | — |
This table shows 8 annual periods of Regencell Bioscience's balance sheet, from FY 2026 back to FY 2019, across 11 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RGC's reporting calendar. What is a balance sheet?